As healthcare systems worldwide prioritize cost-effective chronic disease treatment and improve access to oral anti-diabetic drugs, the Sitagliptin Tablet Market is positioned for sustained expansion. In 2023, the market was valued at USD XX billion, and projections suggest a CAGR of XX% from 2024 to 2032, reflecting rising patient demand, pharmaceutical innovation, and expanding coverage.